Skip to Main content Skip to Navigation
Journal articles

A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations

Abstract : Aim: Ramucirumab, an anti-VEGFR2 monoclonal antibody, has been approved for the treatment of metastatic gastric and colorectal cancer. An assay measuring ramucirumab serum concentrations was needed to investigate its pharmacokinetics and concentration-response relationship. Results: An ELISA was developed and validated according to the international guidelines for ligand-binding assays. Ramucirumab calibration standards ranged from 0.125 to 40 mg/l. Low, middle and high quality controls were spiked at 0.2, 4 and 8 mg/l, respectively. The limits of quantification were established to be 0.125 and 10 mg/l for LLOQ and ULOQ, respectively. No cross-reactivity with anti-VEGF or anti-EGFR was detected. Conclusion: This in-house-developed ELISA is sensitive, accurate, reproducible and suitable for pharmacokinetic studies of ramucirumab.
Complete list of metadata
Contributor : William Raoul <>
Submitted on : Thursday, April 1, 2021 - 2:46:53 PM
Last modification on : Saturday, April 3, 2021 - 3:28:00 AM
Long-term archiving on: : Friday, July 2, 2021 - 6:55:30 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2021-09-26

Please log in to resquest access to the document



Celine Desvignes, David Ternant, Thierry Lecomte, Astrid Lièvre, Marc Ohresser, et al.. A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations. Bioanalysis, Future Science, 2021, 13 (7), pp.565-574. ⟨10.4155/bio-2020-0199⟩. ⟨inserm-03186974⟩



Record views